Inflammatory markers such as cytokines represent potential biomarkers for major depressive disorder (MDD). Many, generally small studies have examined the role of single markers and found significant associations. We assessed 42 inflammatory markers, namely cytokines, in the blood of 321 control subjects and 887 MDD cases. We tested whether individual inflammatory marker levels were significantly affected by MDD case/control status, current episode, or current depression severity, covarying for age, sex, body mass index (BMI), smoking, current antidepressant use, ethnicity, assay batch and study effects. We further used machine learning algorithms to investigate if we could use our data to blindly discriminate MDD patients, or those in a current episode. We found broad and powerful influences of confounding factors on log-protein levels. Notably, IL-6 levels were very strongly influenced by BMI (p = 1.37 x 10 -43 , variance explained = 18%), while Interleukin-16 was the most significant predictor of current depressive episode (p = 0.003, variance explained = 0.9%, q < 0.1). No single inflammatory marker predicted MDD case/control status when a subject was not in a depressed episode, nor did any predict depression severity. Machine learning results revealed that using inflammatory marker data with clinical confounder information significantly increased precision for differentiating MDD patients who were in an episode. To conclude, a wide panel of inflammatory markers alongside clinical information may aid in predicting the onset of symptoms, but no single inflammatory protein is likely to represent a clinically useful biomarker for MDD diagnosis or prognosis.
Introduction
Inflammatory proteins, such as cytokines, are mediators of the immune system and are key in orchestrating appropriate responses to infection. [1] [2] [3] Pro-inflammatory cytokines promote systemic inflammation and are predominantly released by macrophages and T-cells. [4] [5] Interleukin-6 (IL-6) and tumour necrosis factor (TNF) are key examples of pro-inflammatory cytokines released endogenously to combat infection. 4 Chemokines are a subset of smaller cytokines (e.g. interleukin-8), which act as chemotactic factors, and help to direct immune cells, such as neutrophils, to the site of infection, where they can aid in eliminating a pathogen. 1 In contrast, anti-inflammatory cytokines work to reduce inflammation and are important in shutting down the pro-inflammatory state, to assist in wound healing; a key example is interleukin-10 (IL-10) which is primarily synthesized by monocytes. [7] [8] The general inflammatory status of an individual is often characterised clinically by C-reactive protein (CRP), which is an acute phase protein synthesized in the liver, which rises in response to inflammation. 6 In addition to its important role in combatting infection, a pro-inflammatory profile is reportedly associated with a broad range of disease states including diabetes, obesity and cancer. [9] [10] Studies have also reported increased circulating levels of pro-inflammatory cytokines in psychiatric disorder patients, and it has been proposed that cytokines influence neurotransmitter systems and brain functionality related to psychiatric disease pathology. 11 Previous studies of major depressive disorder patients (MDD) have
shown heightened circulating levels of pro-inflammatory cytokines and acute phase proteins, including IL-6, TNF and CRP, and lower levels of the anti-inflammatory cytokine IL-10. [12] [13] [14] [15] In the cases of IL-6, TNF and IL-10, the body of associative evidence with MDD has been drawn from small case-control studies (mainly n < 50) and meta-analyses, many of which only account for the confounding effects of age and gender. [16] [17] [18] [19] [20] Body mass index (BMI), smoking and ethnicity have been found to influence, in some cases very strongly, the circulating levels of cytokines and represent very plausible confounding factors in MDD case-control studies and within-case studies. [25] [26] [27] Especially considering, MDD patients have an increased tendency to smoke, chronic cases having a higher BMI, and MDD prevalence varies amongst different ethnicities. [21] [22] [23] [24] Furthermore, cytokines and acute phase proteins are heavily influenced by each other's expression 28 , and few studies have considered whether cytokines in the wider inflammatory pathway may have a more pervasive association with MDD, than just IL-6 and CRP.
The examination of case-control differences in inflammatory marker (e.g. cytokines) expression within well-characterised cohorts could be useful for two reasons. First, confirmed differences in the expression of specific cytokines, may hint toward an immuno-inflammatory pathophysiology of MDD, allowing for the creation of drugs targeting specific components of the immune system in order to treat it. 29 Secondly, differences in cytokine levels may provide an objective test for an individual's diagnosis and prognosis.
For instance, if heightened cytokine levels precede a severe depressive episode, a cytokine biomarker might allow for treatment to be initiated more rapidly, potentially reducing the risk of suicide . 11 
5
In this study we investigated the utility of 42 inflammatory proteins, namely cytokines, as biomarkers for the prediction of MDD case-control status, current depressive episode, and episode severity, utilising blood serum from 321 control subjects and 887 MDD cases, making this one of the most extensive studies of its kind to-date. We further studied the effects of age, sex, BMI, current smoking, ethnicity, and current antidepressant medication on circulating levels of cytokines, and we used a machine learning approach to examine if inflammatory markers in conjunction with clinical/confounder information could increase the precision of blind MDD discrimination when patients were, and were not, in a depressed episode.
Methods

The Study Sample
Peripheral blood samples utilized here were obtained by venipuncture as part of four separate studies:
SELCoH, HDAO (ClinicalTrials.gov Identifier:NCT00035321), LNBI (ClinicalTrials.gov
Identifier:NCT00795821) and GENDEP. All serum was stored at -80 °C prior to use. Subject information relating to each study is shown in Table 1 and a description of each study is given below.
SELCoH
The South East London Community Health Study (SELCoH) is a population study in London, UK, investigating community health. Within this sample, there were samples collected from 27 families (total n=75) as well as 420 non-related individuals. So far, participants have undergone extensive and repeated phenotypic assessment as part of three separate phases. In the third phase, biological specimens were collected from a subset of participants, which included blood for serum separation. [30] [31] [32] [33] MDD case/control status was characterised using the Clinical Interview Schedule-Revised (CIS-R), which can be used to generate ICD-10 diagnoses. 34 A participant was screened positive for an MDD diagnosis if the CIS-R identified a moderate-to-severe depressive episode in any one of the three interviews. A case was screened positive for a current depressive episode if they were in a moderate-to-severe depressive episode in the third phase (i.e. when blood was collected). 321 control subjects within SELCoH were identified as those with no depression symptoms during any of the three interviews, with no previous diagnosis of a depressive disorder (based on self-report). We further identified a subset of 257 'super controls' who showed no psychiatric symptoms at all (i.e. outside of depression) in any of the three interviews, and no previous history of depression; this subset of controls was used for secondary analyses in a more stringent case-control comparison.
HDAO
The HDAO study was a clinical trial carried out in the United States by Eli Lilly testing the differential effects of fluoxetine, olanzapine, and fluoxetine + olanzapine combinations on therapeutic response in MDD patients. 35 Eligibility criteria included: meeting DSM-IV criteria for recurrent MDD without psychotic features 36 , a current depressive episode, and previous failure to achieve response to an antidepressant other than a selective serotonin reuptake inhibitor. Blood serum was collected from patients at baseline, which we utilise in this study.
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LNBI
The LNBI study was a clinical trial carried out in the United States by Eli Lilly testing the effect of the antidepressant edivoxetine (LY2216684) relative to placebo on major depression symptoms. 37 Eligibility criteria included DSM-IV-TR criteria for MDD without psychotic features 36 , and a current depressive episode as assessed using the Clinical Global Impressions Scale (CGIS). 38 Depression severity was captured using the Montgomery Asberg Depression Rating Scale (MADRS).
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GENDEP
The Genome-based Therapeutics Drugs for Depression (GENDEP) was a 12-week partially randomized open label pharmacogenetic study in European MDD patients, comparing the effects of escitalopram and nortriptyline on symptom improvements. [28] [29] [40] [41] [42] [43] [44] The study consisted of treatment-seeking adults with MDD symptoms of at least moderate severity according to ICD-10 or DSM-IV criteria. 36, 45 Blood serum was collected from patients at baseline, which we utilise in this study. Depression severity was characterized using three rating scales, including the MADRS.
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<<< measurements were acceptably reliable using this methodology. Furthermore, known quantities within the standard curves used on each plate, correlated very highly with quantities predicted by fluorescence intensity (r > 0.99). We additionally validated our methodology by comparing results obtained using an independent method (single ELISA for C-reactive protein) in a independent laboratory in the same sample set 43 , and our results showed a high positive correlation (r > 0.85).
Statistical Analysis (i) Data Processing
Standard curves were used to determine absolute quantities (pg/mL) of each inflammatory marker.
Absolute quantities (pg/mL) were then log-transformed to allow for parametric analyses. We excluded inflammatory markers where greater than 20% of data was missing, as it indicates that these proteins may not be useful as biomarkers. Subsequently, data points were removed if they exceeded +/-2 standard deviations from the mean.
(ii) Identification of marker-specific confounders For each log-protein level, we performed a general linear model to test for the effects of age, sex, BMI, ethnicity, family ID (related to the presence of families in SELCoH) and smoking, alongside batch and study. In a systematic, step-wise fashion we dropped any non-significant covariates (p > 0.05), until we established a list of significant confounders to include in our downstream analyses.
(iii) Case-control & Current Episode analysis
For the case/control comparison, we performed a general linear regression with log-protein level as the dependent variable, major depression case/control status, current depressive episode, and current antidepressant medication as the independent variables, alongside the following covariates: batch/plate effects, study effects, and any other significant confounders identified from (ii). We applied the false discovery rate for multiple testing correction and a q < 0.1 threshold to determine true associations. 46 As a secondary analysis, we also performed the same analysis in a subset of super controls (n=257), who were free from all psychiatric symptoms.
(iv) Depression Severity Analyses
To test the effect of current depression severity on inflammatory marker levels we performed a withincases analysis utilising the LNBI and GENDEP cohorts, and MADRS scores. We performed a general linear regression with log-protein level as the dependent variable, MADRS scores as the independent variable, alongside batch/plate effects, study effects, and any other significant confounders. We applied the false discovery rate of multiple testing correction and a q < 0.1 threshold to determine true associations.
(v) Machine Learning
Finally, to investigate the collective predictive capabilities of inflammatory marker levels on (i) MDD case/control and (ii) current depressive episode, we used machine learning. Initially, we selected only individuals who were medication-free. Only samples with defined values for age, smoking status, BMI, ethnicity and gender were kept. Missing values were imputed using a k nearest neighbours approach with number of neighbours k = 3. For the remaining inflammatory markers, we regressed out the effects of nuisance factors (batch, study) by taking the standardized residuals. For each phenotype (disease status, current episode), we built three sets of variables for the 463 instances: inflammatory markers, "confounders" (age, smoking status, BMI, ethnicity, gender), and inflammatory markers + confounders.
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Each set of variables were separated into training (n=324) and validation sets (n=139). Each training set was used to build several machine learning models evaluated in a 10-fold cross-validation procedure repeated 10 times. The methods included a Naïve Bayes classifier with kernel estimator, Random Forests with 500 or 1000 trees, both implemented in WEKA. The classifiers are cost-sensitive: the training instances were reweighted to account for class imbalance. We selected models with the best precision (Random Forests with 1000 trees, for all sets of variables). This "best" model was then validated on the blinded external validation set. The attribute evaluation method was also performed on the training set to rank the contribution of each variable in contributing to case/control or current episode discrimination.
This was achieved using "ReliefF" implemented in WEKA; instances are sampled randomly and the value of the attribute of the nearest instance of the same and different class is considered.
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Results
(i)
Inflammatory markers adequately detected in serum using our methodology 32 inflammatory proteins passed our quality control criteria. 10 inflammatory markers showed greater than 20% missingness across our samples and were removed from downstream analysis (IL4, MIP-1A,
IFN-a, GM-CSF, IL-1A, IL-13, IL-1B, IL-2, IL-5, IL-8(HA)), Figure 1 shows all inflammatory markers expressed in >80% of our sample. Inter-plate co-efficient of variation (CV) was calculated, which revealed low levels of inter-plate variability for every marker assessed (CV < 2). See S1 in
Supplementary information for details on how the inflammatory markers correlate with one another.
<<<Figure 1>>>>
(ii) Identification of inflammatory marker-specific confounders 
Discussion
There has been much research addressing the potential relationship between a heightened proinflammatory state and MDD. This study was designed as a well-powered replication of the findings reported by smaller case-control studies, which reported differences in levels of cytokines such as IL-6, amongst cases. [16] [17] [18] [19] [20] 48 Our study represents one of most extensive to-date, investigating differences in the expression of 42 inflammatory markers in relation to MDD case-control status, current episode and depression severity in a large cohort of 1,208 individuals. From our study we can draw four main conclusions.
First, in our study, none of the 42 inflammatory markers investigated, represent biomarkers for lifetime presence of MDD, this included CRP or IL-6, Figure 3 . Given the size of the study, it appears unlikely that single inflammatory measures could be used prospectively to identify people at risk for developing 50 Our findings are also reminiscent of the extensive case-control association work performed on functional genetic variants in psychiatric candidate genes (e.g. SERT and COMT), many of which were later disproved as risk factors in far larger, more powerful GWAS. 49 Our third main finding was that few MDD cytokine case-control studies have been adequately powered to consider the possible confounding effects of environmental factors considerably more frequent amongst MDD patients, such as smoking or higher BMI. 21, 22 We studied the influences of these factors in the current study as well as sex, age, ethnicity, and current antidepressant use. Our study very clearly highlights the extensive effects confounding factors have on the expression of inflammatory markers, the association between IL-6 levels and MDD was five times higher when combining results from studies where BMI was not accounted for, suggesting BMI plays a pivotal role in inflating the association between inflammatory markers and MDD. 20 The relationship between IL-6 and MDD has further been investigated by Mendelian randomisation analyses, showing that genetic variants which alter IL-6 levels are not causally associated with MDD. 49 Fourth, despite finding that no individual inflammatory marker was powerfully associated with MDD symptomology, our machine learning results suggest inflammatory data may still confer added predictive value in terms of diagnosis and prognosis. We tested the combinatorial influence of our inflammatory marker data using machine learning and found that both within our cross-validation test and our replication tests, inflammatory markers combined with confounders outperformed the predictive capabilities of confounders alone, Figure 4 . This suggests that information relating to inflammatory markers may improve the precision of diagnoses by 5% when including this information alongside other clinical factors/confounder factors. More striking was that the precision to blindly discriminate an MDD patient in a current episode, increased by 15% when including inflammatory marker data alongside clinical factors (the confounders we examined), Figure 4 . Unlike IL-16, this finding could be important clinically as it confers a substantially higher precision for discriminating those in a current depressed episode. If these inflammatory measures also precede the onset of a depressed episode, this could be used to initiate rapid treatment before depression symptoms fully present themselves. Thus, although our results show that clinical information/confounders such as BMI do strongly influence inflammatory marker expression, including inflammatory information still added independent information capable of improving diagnosis and prognosis of MDD. Future studies should focus on refining and replicating our results, particularly those variables with high attributive merit scores, Figure 5 .
While we acknowledge the strengths of the study, which include strict quality control, outlier removal, the screening of control subjects, the randomisation of cases and controls across batches, controlling for batch and study differences, and considering a number of potential confounding factors on inflammatory marker expression, we should also consider the study's weaknesses. The main weakness of the study is the fact that controls were sampled from a single cohort (SELCoH) that also contained cases, whereas the three additional studies (HDAO, LNBI and GENDEP) were case-only. For each of these four studies there were slightly different blood collection protocols and serum had been stored at -80°C for different periods of time. The population within each sample differed (US, UK only, Europe), and depression caseness was defined slightly differently across the cohorts (but all met criteria for major depressive disorder). Although we corrected for study effects which were consistently significant across our analyses, we may have over-or under-corrected for these differences. Nevertheless, we did correct for study differences and considered this as an appropriate action which was not overly conservative.
Furthermore, a significant proportion of our cases were derived from the same cohort as our controls (SELCoH), allowing us to correct for cohort batch effects effectively.
To conclude, our study suggests that there may be no single inflammatory marker predictors of MDD caseness, current episode or depression severity which would be clinically useful. Strong confounding influences such as BMI may have driven previous associations between cytokines such as IL-6 and MDD. Nevertheless, a machine learning approach incorporating clinical/confounder data alongside inflammatory marker data may have some usefulness in improving MDD discrimination, particularly when an individual is currently in a depressed episode, however this requires further validation.
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